Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma

Chinese Journal of Pathology

Volumn 37, Issue 6, 2008, Pages 371-376

  Xu, Fang Ping ^a   Liu, Yan Hui ^b   Luo, Xin Lan ^b   Zhuang, Heng Guo ^b   Li, Li ^b   Luo, Dong Lan ^b   Xu, Jie ^b   Zhang, Fen ^b   Zhang, Ming Hui ^b   Du, Xin ^b   Li, Wen Yu ^b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b NONE

Author keywords

Gene rearrangement; Gene, bcl 6; Immunophenotype; Lymphoma, B cell; Oligonucleotide array sequence analysis; Prognosis

Indexed keywords

CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GEMININ; KI 67 ANTIGEN; PROTEIN BCL 6;

ARTICLE; B CELL LYMPHOMA; CANCER MORTALITY; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; PROTEIN ANALYSIS; TISSUE MICROARRAY; B LYMPHOCYTE; CHROMOSOME 14; GENE TRANSLOCATION; GENETICS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; PATHOLOGY; PROGNOSIS;

B-LYMPHOCYTES; CHROMOSOMES, HUMAN, PAIR 14; CYCLIN D3; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSLOCATION, GENETIC;

EID: 49149107828     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:171-174.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403(6769):503-511.
3. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A, 2003, 100(17):9991-9996.
4. Poulsen CB, Borup R, Nielsen FC, et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol, 2005, 74(6):453-465.
5. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103(1):275-282.
6. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 2004, 28(4):464-470.
7. Chinese source
8. Liu YH, Xu FP, Zhuang HG, et al. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol, 2008, 39(6):875-884.
9. Chinese source
10. Ye BH, Rao PH, Chaganti RS, et al. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res, 1993, 53(12):2732-2735.
11. Dent AL, Vasanwala FH, Toney LM. Regulation of gene expression by the proto-oncogene BCL-6. Crit Rev Oncol Hematol, 2002, 41(1):1-9.
12. Xu FP, Xie D, Wen JM, et al. SRC-3/AIBI protein and gene amplification levels in human esophageal squamous cell carcinoma. Cancer Lett, 2007, 245(1):69-74.
13. Kaneita Y, Yoshida S, Ishiguro N, et al. Detection of reciprocal fusion 5′-BCL6/partner-3′ transcripts in lymphomas exhibiting reciprocal BCL6 translocations. Br J Haematol, 2001, 113(3):803-806.
14. Barrans SL, O'Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol, 2002, 117(2):322-332.
15. Niitsu N, Okamoto M, Nakamura N, et al. Prognostic impact of chromosomal alteration of 3q27 on nodal B-cell lymphoma: correlation with histology, immunopheno type, karyo type, and clinical outcome in 329 consecutive patients. Leuk Res, 2007, 31(9):1191-1197.
16. Chinese source
17. Chen PM, Yang MH, Yu IT, et al. Low incidence of BCL-6 gene alterations for diffuse large B-cell lymphomas in Taiwan Chinese. Cancer, 2002, 94(10):2635-2644.
18. Ueda C, Akasaka T, Ohno H. Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications. Leuk Lymphoma, 2002, 43(7):1375-1381.
19. Chinese source
20. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas; a prospective Southwest Oncology Group trial. Blood, 1994, 83(6):1460-1466.
21. Sherr CJ. Cancer cell cycles. Science, 1996, 274(5293):1672-1677.
22. Filipits M, Jaeger U, Pohl G, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res, 2002, 8(3):729-733.
23. Allman D, Jain A, Dent A, et al. BCL-6 expression during B-cell activation. Blood, 1996, 87(12):5257-5268.
24. Shaffer AL, Yu X, He Y, et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity, 2000, 13(2):199-212.
25. Ranuncolo SM, Polo JM, Dierov J, et al. bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol, 2007, 8(7):705-714.